Only one issue mutation, V6A, introduced in the molecule drastically enhanced the toxicity profile and lessened VLS in comparison with the WT molecule [76]. Extra studies and clinical trials will be necessary to determine if this modified build has enhanced safety and efficacy in human beings. Th